Skip to content

Aura Biosciences, Inc. AURA Total Liabilities

Total Liabilities at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$119.71B+3.6%
Merck & Co. logo
Merck & Co.MRK
$229M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.52B+69.5%
UroGen Pharma logo
UroGen PharmaURGN
$377.94M+28.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$93.08M+21.7%
CG Oncology logo
CG OncologyCGON
$43.48M+85.6%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s total liabilities?
Aura Biosciences, Inc. (AURA) reported total liabilities of $30.43M in Q1 2026.
How has Aura Biosciences, Inc.'s total liabilities changed year-over-year?
Aura Biosciences, Inc.'s total liabilities increased by 10.9% year-over-year, from $27.44M to $30.43M.
What is the long-term trend for Aura Biosciences, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s total liabilities has grown at a 64.0% compound annual growth rate (CAGR), from $2.74M to $32.52M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.